# A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor

> **NCT06166472** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 72 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** AK132

## Key facts

- **NCT ID:** NCT06166472
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2026-04-24
- **Final completion:** 2026-07-24
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06166472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06166472, "A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06166472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*